Novartis Raises FullYear Sales and Profit Guidance Amid Strong Operational Performance SpaceX and OpenAI Potential Public Debuts May Surpass Berkshire Hathaways Market Cap on Day One Cramers Morning Meeting Buy Sell and a Stock with Potential 30 Upside Intuits Latest Earnings Results Test Morgan Stanleys Stock Projection Strategy Inc Pauses Bitcoin Accumulation Prioritizes 15B Bond Repurchase Lynas Rare Earth Deal with Pentagon Sparks Controversy in Malaysia IPW Q3 2025 Earnings EPS Misses Estimates Amidst Revenue Disclosure Gap Stock Slides 82 Leonardo DRS Inc DRS Q1 2026 Earnings EPS Beat Drives Modest Stock Gain Nasdaq Inc Q1 2026 Earnings EPS Slightly Exceeds Street Estimates Amid Steady Performance Cognyte CGNT Q1 2026 Earnings EPS Soars Past Estimates with 126 Surprise LPX Q1 2026 Earnings Massive EPS Surprise Drives Modest Stock Gains SBAC Q1 2026 Earnings EPS Misses Estimates Amid Challenging Leasing Environment Maplebear Inc CART Experiences Modest Pullback as It Tests Key Support Levels Income Opportunity Realty Investors IOR Holds Steady at 1785 Amid Consolidation Universal Display OLED Slips 115 Testing Key Support at 8768 Eaton Vance TaxAdvantage Global Dividend Opp ETO Flat Trading as Dividend Stock Holds Key Support GigaCloud Technology GCT Holds Steady Near Support Sideways Trading Signals Caution Global Markets Hit Record Highs Oil Declines on USIran Peace Hopes Pagaya Technologies PGY Q1 2026 Earnings Massive EPS Surprise Masks Mixed Operational Signals Vendome Acquisition Corp I VNME Holding Steady at 1017 Amid SPAC Market Stability ELTK Q1 2026 Earnings EPS Reports a Loss Stock Shows Resilience ATER Q3 2025 Earnings EPS Surpasses Estimates by Over 56 Stock Rises JILL Q1 2026 Earnings Narrower Loss Beats Expectations Shares Rise Gogo Inc GOGO Q1 2026 Earnings EPS Beat Drives Modest Stock Uptick Amid Revenue Disclosure Gap SCZM Q1 2026 Earnings EPS Misses Estimates Amid Operational Headwinds Stock Edges Higher FTRE Q1 2026 Earnings Earnings Beat Expectations with 241 Surprise INAB Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Stage Company Advances Pipeline